In The Lancet Diabetes & Endocrinology, Mengmeng Li and colleagues analysed global trends in thyroid cancer incidence from 2003 to 2017 and contemporary burden for the year 2022 among adolescents and ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced ...

Earnings call Pulse Biosciences posted its first commercial revenue of $86K in Q3 2025, driven by limited release of its M-Pulse Vibrance system. GAAP net loss widened to $19.4M due to clinical and ...

SOUTH SAN FRANCISCO, Calif., November 03, 2025--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today announced the publication of two studies demonstrating the ...

MICROWAVE ablation (MWA) offers a safe and effective non-surgical treatment for benign thyroid nodules, with high volume reduction rates and promising outcomes for autonomously functioning thyroid ...

Sarasota Memorial Hospital is part of a study on a new ablation treatment for non-cancerous thyroid nodules. The study uses Nanosecond Pulsed Field Ablation technology to destroy abnormal tissue while ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or ...

Department of Pathology, The 923rd Hospital of the Chinese People’s Liberation Army Joint Logistics Support Force, Nanning, China. Currently, commercial platforms include ThinPrep (Hologic), SurePath ...

JOHNSTOWN, Pa. (WTAJ) — Up to 60% of people will develop thyroid nodules by the age of 60, and while most don’t cause any symptoms, for some, they can make it difficult to swallow, breathe and speak.

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today ...

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful ...